You are now leaving GSK’s website

This link will take you to a non-GSK website. GSK does not recommend, endorse or accept liability for sites controlled by third-parties.

Continue

Go back

Ellipta inhaler products

With over 40 ways to construct a triple therapy in 2019, we recognise the complexity that you face in your practice. That is why we have developed a portfolio of evidence-based medicines, all delivered in the same easy-to-use device. 1

To find out how the Ellipta portfolio can help your patients, explore the products below:

Trelegy Ellipta (fluticasone furoate / umeclidinium / vilanterol)

Prescribing information

COPD

Trelegy Ellipta is indicated as a maintenance treatment in adult patients with moderate to severe COPD who are not adequately treated by a combination of an inhaled corticosteroid (ICS) and a long-acting β2-agonist (LABA) or a combination of a long-acting muscarinic antagonist (LAMA) and a long-acting β2-agonist (LABA). 2

Anoro Ellipta (umeclidinium / vilanterol inhalation powder)

Prescribing information

COPD

Anoro is indicated as a maintenance bronchodilator treatment to relieve symptoms in adult patients with chronic obstructive pulmonary disease (COPD). 3

Relvar Ellipta (fluticasone furoate/vilanterol inhalation powder)

Prescribing information

Asthma

Relvar Ellipta (92 micrograms/22 micrograms inhalation powder and 184 micrograms/22 micrograms inhalation powder) is indicated for the regular treatment of asthma in adults and adolescents aged 12 years and older where use of a combination medicinal product (long-acting beta2-agonist and inhaled corticosteroid) is appropriate: patients not adequately controlled with inhaled corticosteroids and 'as needed' inhaled short acting beta2-agonists; patients already adequately controlled on both inhaled corticosteroid and long-acting beta2-agonist. 4

Incruse Ellipta (umeclidinium bromide inhalation powder)

Prescribing information

COPD

Incruse Ellipta is indicated for the ‘maintenance bronchodilator treatment to relieve symptoms in adult patients with chronic obstructive pulmonary disease (COPD). 5

 

Other products in our Respiratory portfolio

View More

References

  1. Van der Palen, J., et al., NPJ Primary Care Respiratory Medicine, 2016. 26: p. 16079.
  2. GlaxoSmithKline UK. Trelegy Ellipta 92/55/22 mcg inhalation powder Summary of Product Characteristics.
  3. GlaxoSmithKline UK. Anoro Ellipta 55/22 mcg inhalation powder, pre-dispensed Summary of Product Characteristics.
  4. GlaxoSmithKline UK. Relvar Ellipta 92/22 mcg inhalation powder, pre-dispensed Summary of Product Characteristics.
  5. GlaxoSmithKline UK. Incruse 55 mcg inhalation powder, pre-dispensed Summary of Product Characteristics.

Anoro, Incruse, Relvar, Trelegy and Ellipta are registered trademarks of the GlaxoSmithKline group of companies